CRISPR offers new hope for many patients and promises to transform the way we think of
future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical …

CRISPR-Cas clinical trials have begun, offering a first glimpse at how DNA and RNA
targeting could enable therapies for many genetic and epigenetic human diseases. The …

A series of recent discoveries harnessing the adaptive immune system of prokaryotes to
perform targeted genome editing is having a transformative influence across the biological …

Genome‐editing therapeutics are poised to treat human diseases. As we enter clinical trials
with the most promising CRISPR‐Cas9 and CRISPR‐Cas12a (Cpf1) modalities, the risks …

The prokaryote-derived CRISPR–Cas genome editing systems have transformed our ability
to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells …

One of the fundamental discoveries in the field of biology is the ability to modulate the
genome and to monitor the functional outputs derived from genomic alterations. In order to …

Cancer is one of the most leading causes of mortalities worldwide. It is caused by the
accumulation of genetic and epigenetic alterations in two types of genes: tumor suppressor …

Since first proposed as a new tool for gene targeting and genome editing, CRISPR
technology has quickly advanced into the clinical stage. Initial studies highlight the potential …

First introduced into mammalian organisms in 2013, the RNA-guided genome editing tool
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR …

Gene therapy carries the potential to treat more than 10,000 human monogenic diseases
and benefit an even greater number of complex polygenic conditions. The repurposing of …